Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating filgotinib in biologic DMARD-naive active psoriatic arthritis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Filgotinib (filgotinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Psoriatic Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2022-05-16